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ABSTRACT
Prognosis of patients with lung metastases of soft-tissue sarcoma is still poor. 
Therefore, novel systemic therapy is needed to improve the survival of soft-tissue 
sarcoma. In the present study, tumor-targeting therapy with a genetically-modified 
auxotrophic strain of Salmonella typhimurium, termed A1-R, was evaluated. Mouse 
models of primary soft tissue sarcoma and spontaneous lung metastasis were 
obtained by orthotopic intra-muscular injection of HT1080-RFP human fibrosarcoma 
cells. S. typhimurium A1-R was administered from day 14, once a week for two weeks. 
On day 28, lung samples were excised and observed with a fluorescence imaging 
system. The number of lung metastasis was 8.8 ± 3.4 in the untreated group and 0.8 ± 
0.8 in the treated group (P = 0.024). A mouse model of experimental lung metastasis 
was obtained by tail vein injection of HT1080-RFP cells. The mice were treated with 
S. typhimurium A1-R (i.v.) on day 7, once a week for three weeks. S. typhimurium 
A1-R significantly reduced lung metastases and improved overall survival (P = 0.004). 
S. typhimurium A1-R bacterial therapy has future potential for treating advanced soft 
tissue sarcoma and improving prognosis of patients with lung metastasis.
INTRODUCTION
The 5-year survival rate of the patients with lung 
metastases from soft-tissue sarcoma is 15.5% [1]. 
Systemic control of soft tissue sarcoma is necessary in 
the treatment of this disease. Although chemotherapy 
is widely used as the systemic treatment for soft tissue 
sarcoma, it has failed to show long-term survival benefits 
[2]. Therefore, novel systemic therapy is needed to 
improve the outcome of soft tissue sarcoma.
Our laboratory developed a Salmonella typhimurium 
(S. typhimurium) A1-R strain that has high tumor-
colonization and antitumor efficacy. S. typhimurium 
A1-R is auxotrophic for leu-arg, which prevents it from 
continuously infecting normal tissues. S. typhimurium 
A1-R has no other apparent attenuating mutations 
S. typhimurium A1-R could eradicate primary and 
metastatic tumors as monotherapy in nude mice with 
prostate [3, 4], breast [5], lung [6, 7] and pancreatic 
[8, 9] cancers, including pancreatic cancer stem cells 
[10] and pancreatic cancer patient-derived orthotopic 
xenografts [PDOX] [11], as well as sarcoma [12, 13] and 
glioma [14, 15].
Treatment with tumor-targeting S. typhimurium 
A1-R completely prevented the appearance of bone 
metastasis of a high metastatic variant of breast cancer in 
nude mice [16].
 In our previous study, S. typhimurium A1-R 
was administered i.v. to nude mice which had primary 
osteosarcoma bone tumor and lung metastasis. The primary 
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bone tumor developed after orthotopic intra-tibial injection 
of 143B-RFP (red fluorescent protein) human osteosarcoma 
cells. S.typhimurium A1-R was effective against both the 
primary bone tumor and lung metastasis [13].
S. typhimurium A1-R, expressing green fluorescent 
protein (GFP), was administered to nude mice with 
popliteal lymph node metastasis of human HT-
1080 fibrosarcoma as well as lung metastasis of the 
fibrosarcoma. S. typhimurium A1-R was delivered via a 
lymphatic channel to target the lymph node metastases and 
systemically via the tail vein to target the lung metastasis. 
The sarcoma cells expressed RFP in the cytoplasm and 
GFP in the nucleus linked to histone H2B, enabling color-
coded real-time imaging of the GFP-expressing bacteria 
targeting the metastases. After 7–21 days of treatment, 
the metastases were eradicated without the need of 
chemotherapy or any other treatment. No adverse effects 
were observed [12].
Intratumoral injection of Clostridium novyi spores with 
the toxin gene knocked out (C. novyi-NT) was administered 
to dogs with solid tumors. Responses were observed in 6 of 
16 dogs. A human patient with advanced leiomyosarcoma 
was treated with an intratumoral (i.t.) injection of C. novyi-
NT spores which reduced the tumor’s size [17]. However, 
obligate anaerobes such as C. novyi or Bifidobactum [18] 
may not be appropriate for metastatic cancer since they are 
seemingly only active with i.t. administration. If bacterial 
therapy is going to be widely available and efficacious, it has 
to target metastatic cancer.
In the present study, we determined the efficacy of 
S. typhimurium A1-R on primary tumors and experimental 
and spontaneous metastasis in mouse models of human 
soft-tissue sarcoma.
RESULTS AND DISCUSSION
Color-coded imaging of the interaction of 
S. typhimurium A1-R-GFP with RFP-expressing 
HT-1080 fibrosarcoma cells
The interaction between S. typhimurium A1-R 
expressing GFP and HT-1080 fibrosarcoma cells 
labeled with RFP was observed with the Fluoview 
FV1000 confocal microscope (Olympus Corp., Tokyo, 
Japan). GFP-expressing S. typhimurium A1-R invaded 
the fibrosarcoma cells (Fig.1a) and proliferated in the 
cytoplasm (Fig. 1b). The proliferation of S. typhimurium 
A1-R in the cytoplasm of fibrosarcoma cells induced cell 
death (Fig. 1c, d).
Specific targeting of S. typhimurium A1-R to soft 
tissue sarcoma in vivo
HT1080-RFP cells (1 × 106 per mouse) in Matrigel 
(5 µl) (BD Bioscience, San Jose, CA) were injected 
into the left femoral muscle. On day 14, S. typhimuium 
A1-R was injected into the tail vein. Three days after 
S. typhimuium A1-R injection, the left femoral muscle 
with tumor and right femoral muscle without tumor 
were resected and minced in 1 ml PBS. The PBS 
containing muscle and/or tumor tissue was diluted and 
cultured on plates with LB agar. After 24 h culture, 
S. typhimuium A1-R colony formation was observed 
with the OV100 Small Animal Imaging System 
(Olympus Corp.) [19] by GFP expression (Fig. 2). 
These results demonstrated that S. typhimuium A1-R 
selectively targeted and survived only in the tumor 
tissue.
Efficacy of S. typhimuium A1-R on primary 
soft tissue sarcoma and spontaneous lung 
metastases
Mice transplanted with HT1080-RFP cells in the 
leg muscle developed primary soft tissue tumor and lung 
metastasis (Fig. 3). Fourteen days after tumor injection, 
the RFP tumor was confirmed by imaging with the iBOX 
(UVP, LLC, Upland, CA). S. typhimurium A1-R was 
administered on days 14 and 21 after transplantation. 
On day 28, the fluorescent area of the tumor and lung 
metastasis was determined with the OV100. The 
fluorescent area of the primary tumor was 481 ± 59 mm2 
in the untreated group and 176 ± 42 mm2 in the treated 
group (P < 0.001) (Fig. 4a, b). The fluorescence intensity 
of the treated group was 18.7% of the untreated group 
(P = 0.003) (Fig. 4b). The primary tumor size was 4750 
± 612 mm3 in the untreated group and 867 ± 273 mm3 
in the treated group (P < 0.001) (Fig. 4d). The primary 
tumor weight was 5.7 ± 1.0 g in the untreated group and 
was 1.5 ± 0.4 g in the treated group (P = 0.001) (Fig. 4e). 
To evaluate the efficacy of S. typhimurium A1-R on 
spontaneous lung metastases, the lungs were excised 
and the metastases on the surface were counted with the 
OV100 (Fig. 5a). The number of metastasis was 8.8 ± 3.4 
per mouse in the untreated group and 0.8 ± 0.8 in the 
treated group (P = 0.024) (Fig. 5b).
Efficacy of S. typhimurium A1-R on fibrosarcoma 
experimental lung metastasis
HT1080-RFP cells (1 × 106 cells in 100 µl PBS) 
were injected into the tail vein of 24 nude mice (day 0) 
(Fig. 6a). On days 7, 14, and 21, S. typhimurium A1-R 
(5 × 107 CFU per mouse) was injected into the tail vein 
(Fig. 6b). On day 28, 6 mice (3 mice of each group) 
were sacrificed and the lungs were imaged to determine 
the efficacy of bacterial therapy on lung metastases. 
Fluorescence imaging demonstrated that S. typhimurium 
A1-R strongly inhibited lung metastases (Fig. 6c). The 
mean fluorescence intensity of lung metastases of the 
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Figure 1: Efficacy of S. typhimurium A1-R on HT-1080 fibrosarcoma cells in vitro. (a) Early interaction of S. typhimurium  
A1-R-GFP and HT-1080-RFP cells. (b) Increase of S. typhimurium A1-R-GFP in the cytoplasm of HT-1080-RFP cells. (c) Apoptosis of HT-
1080-RFP cells induced by S. typhimurium A1-R. (d) Fragmentation of cytoplasm of S. typhimurium A1-R-GFP-treated HT-1080-RFP cells.
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Figure 2: Selective tumor-targeting of S. typhimurium A1-R. (a) S. typhimurium A1-R-GFP colonies derived from muscle with 
or without tumor after S. typhimurium A1-R treatment. (b) Number of S. typhimurium A1-R-GFP in muscle with or without tumor. GFP-
expressing S. typhimurium A1-R colonies were counted. The colonies were obtained from the tumor tissue after it was minced, diluted with 
PBS and cultured on ager plates. Normal muscle tissue, from the opposite leg of the mouse treated with S. typhimurium A1-R, did not yield 
observable bacterial colonies after mincing, dilution with PBS and culture on agar plates. The S. typhimurium A1-R colonies were observed 
by their GFP fluorescence. The total number of bacteria was calculated by multiplying the colonies observed by the dilution factor carried 
out before plating.
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control mice and S. typhimurium A1-R treated mice 
was 3.9 × 106 and 4.8 × 103, respectively, an almost 
1,000-fold decrease in the treated mice (P = 0.053; 
Fig. 6d). The fluorescence area of the lung metastases 
of control mice and S. typhimurium A1-R-treated mice 
was 112.4 ± 48.1 mm2 and 3.3 ± 2.7 mm2, respectively 
(P = 0.043; Fig. 6d). Kaplan–Meier analysis with the 
log rank test demonstrated that S. typhimurium A1-R 
significantly improved the survival of the treated mice 
(P = 0.004; Fig. 6e).
In the present study, two models of soft-tissue 
lung metastasis comprising spontaneous metastasis and 
experimental metastasis were used to assess the efficacy 
of S. typhimurium A1-R. In the orthotopic spontaneous 
metastasis model of soft tissue sarcoma, S. typhimurium 
A1-R significantly inhibited primary tumor growth 
Figure 3: Efficacy determination of S. typhimurium A1-R on an orthotopic mouse model of HT-1080 soft tissue 
fibrosarcoma. (a) Orthotopic mouse model of HT-1080 soft tissue fibrosarcoma. (b) Treatment protocol of S. typhimurium A1-R on the 
orthotopic model of soft-tissue sarcoma.
Oncotarget12854www.impactjournals.com/oncotarget
(Continued )
Figure 4: Efficacy of S. typhimurium A1-R on an orthotopic mouse model of HT-1080 soft-tissue fibrosarcoma. 
(a) S. typhimurium A1-R inhibition of soft-tissue sarcoma primary tumor growth on day 28 after implantation. (b) Fluorescent areas of soft-
tissue sarcoma primary tumor growth with or without S. typhimurium A1-R treatment on day 28 after implantation.
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Figure 4 (Continued ): (c) Fluorescence intensity of soft-tissue sarcoma tumors with or without S. typhimurium A1-R 
treatment on day 28 after implantation. (d) Tumor size with or without S. typhimurium A1-R treatment on day 28 after 
implantation. (e) Tumor weight with or without S. typhimurium A1-R treatment on day 28 after implantation.
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Figure 5: Efficacy of S. typhimurium A1-R on spontaneous lung metastasis of HT-1080-RFP soft-tissue sarcoma. 
(a) Fluorescence imaging of spontaneous lung metastases from control and S. typhimurium A1-R-treated mice. (b) Number of lung 
metastases in control and S. typhimurium A1-R-treated mice.
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and spontaneous lung metastases. The experimental 
lung metastasis model was used to assess the direct 
effect of S. typhimurium A1-R on lung colonization. S. 
typhimurium A1-R strongly inhibited lung colonization. 
Furthermore, S. typhimurium A1-R significantly improved 
the survival of the mice.
Thus, S. typhimurium A1-R directly inhibits primary 
tumor growth and metastasis of soft-tissue sarcoma. The 
present study suggests that S. typhimurium A1-R therapy 
has superior potential for the systemic treatment of soft 
tissue sarcoma metastasis than C. novyi (NT) that appears 
to be limited to i.t, injection [17]. The comparison of the 
anti-tumor and anti-metastatic efficacy of the two types of 
bacteria will require future clinical trials.
MATERIALS AND METHODS
Preparation of S. typhimurium A1-R
GFP-expressing Salmonella typhimurium A1-R 
(AntiCancer Inc., San Diego, CA, USA) were grown 
overnight in LB medium (Fisher Sci., Hanover Park, IL, 
USA) and then diluted 1:10 in LB medium. Bacteria were 
harvested at late-log phase, washed with PBS, and then 
Figure 6: Efficacy of S. typhimurium A1-R on experimental lung metastasis of fibrosarcoma. (a) Mouse model of soft-tissue 
sarcoma experimental lung metastasis. (b) Treatment protocol.
(Continued)
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Figure 6 (Continued ): (c) Fluorescence imaging of lung metastases with and without S. typhimurium A1-R treatment. 
(d) Fluorescence intensity and area of soft-tissue sarcoma lung metastases. BF = brightfield.
(Continued)
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diluted in PBS [3, 5]. Bacteria were then ready for in vitro 
or in vivo experiments.
Efficacy of S. typhimurium A1-R on 
HT1080 fibrosarcoma cells in vitro
To evaluate the ability of S. typhimurium A1-R to 
kill human fibrosarcoma cells in vitro, the interaction 
between S. typhimurium A1-R expressing GFP and 
HT1080-RFP cells was observed with the Fluoview 
FV1000 confocal microscope (Olympus Corp., Tokyo, 
Japan). HT1080-RFP cells were cultured in 35 mm 
dishes for 24 h. S. typhimurium A1-R bacteria were grown 
in LB and added to the fibrosarcoma cells (1 × 108 CFU/
dish or 1 × 109 CFU/dish). After 1 h incubation at 37°C, 
the cells were rinsed and cultured in medium containing 
gentamycin sulfate (100 µg/ml) to kill external but not 
internal bacteria [3].
Animals
Athymic (nu/nu) nude mice (AntiCancer, Inc. San 
Diego, CA) were used in this study. Mice were kept in a 
barrier facility under high efficiency particulate air (HEPA) 
filtration. Mice were fed with autoclaved laboratory 
rodent diet. All animal studies were conducted in 
accordance with the principles and procedures outlined in 
the National Institutes of Health Guide for the Care and Use 
of Laboratory Animals under Assurance no. A3873-1.
Orthotopic mouse model of soft tissue sarcoma
Six-week old female nude mice were anesthetized 
by a ketamine mixture (10 µl ketamine, HCL, 7.6 µl 
xylazine, 2.4 µl acepromazine maleate and 10 µl H2O) 
via s.c. injection. The leg was sterilized with alcohol 
and an approximately 2 mm midline skin incision was 
made just above the knee joint to expose the quadriceps 
femoris muscle. HT1080-RFP cells (1 × 106 per mouse) in 
Matrigel (5 µl per mouse) (BD Bioscience, San Jose, CA) 
were injected into the muscle with a 0.5 ml 28 G latex-free 
insulin syringe (TYCO Health Group LP, Mansfield, MA). 
The skin was closed with a 6-0 suture. On day 14 and 21, 
S. typhymurium (5 × 107 CFU per mouse) was injected 
into the tail vein. On day-28, the mice were sacrificed 
and fluorescence imaging was performed to determine 
the efficacy of bacterial therapy for both primary tumors 
and lung metastases. The size of the primary tumors 
Figure 6 (Continued ): (e) Kaplan-Meier survival curve of mice with soft-tissue sarcoma treated with S. typhimurium A1-R 
compared to control untreated mice.
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(fluorescent area [mm2]) was measured with the iBox 
Imaging System (UVP LLC, Upland, CA, USA). The 
lung tumor was excised and the metastases on the surface 
were imaged and counted with the OV100 Small Animal 
Imaging System (Olympus Corp., Tokyo, Japan).
Experimental lung metastasis model 
of soft tissue sarcoma
Six-week-old female nude mice were used. To 
obtain experimental lung metastasis, HT1080-RFP cells 
(1 × 106 cells in 100 µl PBS) were injected into the tail 
vein of 24 nude mice (day 0). On days 7, 14, and 21, 
S. typhimurium A1-R (5 × 107 CFU) was injected in the 
tail vein. Twelve mice were treated with bacteria and 12 
mice were used as untreated control. On day 28, 6 mice 
(3 mice each group) were sacrificed and the lungs were 
imaged to observe lung metastases and to determine 
the efficacy of bacterial therapy. Lung metastases were 
observed and the fluorescent areas were recorded using the 
OV100. Additionally, 18 mice comprising 9 control mice 
and 9 S. typhimurium A1-R-treated mice were observed 
for survival analysis.
Statistical analysis
Data showing comparisons between two groups 
were assessed using the Student’s t-test. Kaplan–Meier 
analysis with the log-rank test was used to determine 
survival difference between treatment groups. Differences 
were considered significant when p ≤ 0.05. The 
experimental data are expressed as the mean ± SE.
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